Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
hormone receptor hr positive human epidermal receptor 2 her2 negative breast cancer epidemiology forecast

hormone-receptor-hr-positive-human-epidermal-receptor-2-her2-negative-breast-cancer-epidemiology-forecast-report

SALE

Metastatic HR+/HER2- Breast Cancer - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 60

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

Metastatic HR+/HER2- Breast Cancer Epidemiology

HR+/HER2- breast cancer accounts for ~65–70% of all breast cancers, and incidence increases with increasing age.
At the time of diagnosis, ~64% of breast cancer patients have local-stage breast cancer, 27% have regional stage, and 6% have distant (metastatic) disease in the US. The same percentage of metastatic disease has been observed in Europe and Japan.
As per the analysis, around 76% of patients progress from first-line to second-line setting, and around 71% progress from second to third-line and above.
Breast cancer incidence and death rates increase with age until the seventh decade. The decrease in incidence rates in women 80 years of age and older may reflect lower screening rates, the detection of cancers by mammography before 80 years of age, and/or incomplete detection.
In the US, from the mid-2000s, invasive breast cancer in women has increased by ~0.5% yearly. This is likely caused by an increase in excess body weight in women overall, as well as a drop in fertility rates and rising age for first births.
In France, the incidence of invasive breast cancer increased annually by ~0.8% in all age groups combined from 1990 to 2018.
In Japan, there is a marked and ongoing increase in the incidence of breast cancer. While the specific reasons for this rise remain uncertain, it is well-established that female hormones play a pivotal role in the development and growth of breast cancer. Additionally, the genetic background of individuals is closely intertwined with their susceptibility to this disease.

DelveInsight’s “Metastatic HR+/HER2- Breast Cancer Epidemiology – 2034” report delivers an in-depth understanding of HR+/HER2- Breast Cancer historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2021-2034

Metastatic HR+/HER2- Breast Cancer Disease Understanding

HR+/HER2- Breast Cancer Overview

HR+/HER2- breast cancer is the most common subtype of breast cancer, characterized by cancer cells with hormone receptors for estrogen and progesterone but lacking the overexpression of HER2. This subtype generally has a better prognosis and is often treated with hormone therapy to block hormone-driven growth. Surgery and radiation may be used to remove or target tumors, while chemotherapy and targeted therapies like CDK4/6 inhibitors may be considered for more advanced cases. Early detection is crucial, and support from healthcare providers and family is vital for coping with the diagnosis of HR+/HER2- breast cancer.

Metastatic HR+/HER2- Breast Cancer Diagnosis

A patient’s journey through HR+/HER2- breast cancer diagnosis typically begins with the recognition of concerning symptoms, leading to clinical evaluation and imaging tests. A biopsy confirms the diagnosis and determines the cancer’s characteristics. Staging tests assess the cancer’s extent, guiding a multidisciplinary team in devising a personalized plan, often involving hormone therapy, surgery, radiation, and possibly chemotherapy or targeted therapies. Emotional support plays a crucial role in managing the emotional toll of the diagnosis, and follow-up care ensures ongoing monitoring and adjustment of diagnosis as needed, fostering hope for successful recovery and survivorship.

Further details related to diagnosis are provided in the report...

Metastatic HR+/HER2- Breast Cancer Epidemiology

The HR+/HER2- Breast Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incidence of breast cancer, incident cases of HR+/HER2- breast cancer, the menopausal status of HR+/HER2- breast cancer, stage-specific cases of HR+/HER2- breast cancer, age-specific cases of HR+/HER2- breast cancer and treatment-eligible Pool for HR+/HER2- Breast Cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

According to the estimates, the total incident population of HR+/HER2- Breast Cancer in the 7MM was nearly 476,000 cases in 2023. The cases in the 7MM are expected to increase during the study period, i.e., 2021-2034.
The HR+/HER2- breast cases were highest in the United States, accounting for ~208,400 cases.
According to the estimates, most cases of HR+/HER2- Breast Cancer occur in people aged between 60 and 79 years in the United States, which accounted for ~48% of the cases. Whereas the lowest number of cases were in the age group of <40, which was ~4%.
Among EU4 and the UK, Germany had the maximum total incident cases of HR+/HER2- Breast Cancer, with ~50,200 cases in 2023, while Spain accounted for the least number of cases.
In 2023, in Japan, there were approximately 43,000 treatment-eligible cases of HR+/HER2– breast cancer.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the HR+/HER2- breast cancer evolving epidemic dynamics, patient reliance on conventional therapies, or patient therapy switching acceptability, including oncologists, radiation oncologists, surgical oncologists, and others.

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Institute for Personalized Cancer Therapy, Anderson Cancer Center, Aichi Cancer Center, University Hospital Ulm, International Breast Cancer Center, etc., were contacted. Their opinion helps understand and validate HR+/HER2- breast cancer epidemiology trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the epidemiology and the unmet needs.

Scope of the Report

The report covers a segment of key events, an executive summary, and a descriptive overview of HR+/HER2- breast cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, disease progression, and diagnostic guidelines has been provided.
The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
A detailed review of current challenges in establishing the diagnosis.

Stay ahead with in-depth analysis of the Metastatic HR+/HER2− Breast Cancer Market Forecast-discover emerging therapies, epidemiology data and growth opportunities.

Metastatic HR+/HER2- Breast Cancer Report Insights

Metastatic HR+/HER2- Breast Cancer Patient Population
Country-wise Epidemiology Distribution
Incident cases of HR+/HER2- breast cancer

Metastatic HR+/HER2- Breast Cancer Report Key Strengths

11 Years Forecast
The 7MM Coverage
HR+/HER2- breast cancer Epidemiology Segmentation

Metastatic HR+/HER2- Breast Cancer Report Assessment

Current Metastatic HR+/HER2- Breast Cancer Treatment Practices

Key Questions

What are the disease risks, burdens, and unmet needs of HR+/HER2- breast cancer?
What will be the growth opportunities across the 7MM concerning the patient population with HR+/HER2- breast cancer?
What is the historical and forecasted HR+/HER2- breast cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
At what CAGR the population is expected to grow across the 7MM during the study period (2021-2034)?
Out of the above-mentioned countries, which country would have the highest incident population of HR+/HER2- breast cancer during the study period (2021-2034)

Reasons to Buy

Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
HR+/HER2- breast cancer epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Stay Updated with us for Recent Articles:-

1 Key Insights

2 Report Introduction

3 Executive Summary of HR+/HER2-negative

4 Epidemiology Forecast Methodology

5 Key Events

6 Metastatic HR+/HER2- Breast Cancer Epidemiology Overview at a Glance

6.1 Patient Share (%) Distribution in the 7MM in 2023

6.2 Patient Share (%) Distribution in the 7MM in 2034

7 Disease Background and Overview

7.1 Introduction

7.2 Types of Breast Cancer

7.2.1 Subtypes of Breast Cancer

7.2.2 Molecular Subtypes of Breast Cancer

7.3 Estrogen Receptor (ER)-Positive Breast Cancer

7.3.1 Estrogen Receptor

7.3.2 Estrogen Receptor 1 Mutations

7.4 Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer

7.4.1 Role of Estrogen Receptor Alpha (ERa) in Regulating Breast Cancer Metabolism

7.5 Symptoms of HR-Positive Breast Cancer

7.6 Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer

7.7 Characterization of HER2-low Breast Cancers

7.7.1 Biology of HER2-low Breast Cancer

7.8 Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer

7.9 Diagnostic Guidelines

7.9.1 Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update 2021

7.9.2 Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

8 Epidemiology and Patient Population

8.1 Key Findings

9 Assumptions and Rationale

9.1 Total Incident Cases of Breast Cancer in the 7MM

9.2 Total Incident Cases of HR+/HER2– Breast Cancer in the 7MM

9.3 The United States

9.3.1 Total Incident Cases of Breast Cancer in the United States

9.3.2 Incidence of HR+/HER2– Breast Cancer in the United States

9.3.3 Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in the United States

9.3.4 Stage-specific Incidence of HR+/HER2– Breast Cancer in the United States

9.3.5 Age-specific Incidence of HR+/HER2– Breast Cancer in the United States

9.3.6 Treatment-eligible Pool for HR+/HER2– Breast Cancer in the United States

9.4 EU4 and the UK

9.4.1 Total Incidence of Breast Cancer in EU4 and the UK

9.4.2 Incidence of HR+/HER2– Breast Cancer in EU4 and the UK

9.4.3 Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in EU4 and the UK

9.4.4 Stage-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK

9.4.5 Age-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK

9.4.6 Treatment-eligible Pool for HR+/HER2– Breast Cancer in EU4 and the UK

9.5 Japan

9.5.1 Total Incidence of Breast Cancer in Japan

9.5.2 Incidence of HR+/HER2– Breast Cancer in Japan

9.5.3 Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in Japan

9.5.4 Stage-specific Incidence of HR+/HER2– Breast Cancer in Japan

9.5.5 Age-specific Incidence of HR+/HER2– Breast Cancer in Japan

9.5.6 Treatment-eligible Pool for HR+/HER2– Breast Cancer in Japan

10 Patient Journey

11 Appendix

11.1 Bibliography

11.2 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of HR+/HER2- Breast Cancer Epidemiology (2021-2034)

Table 2: The ASCO 2021 Focused Guideline Update

Table 3: Systemic Therapy for ER- and/or PR-positive Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease

Table 4: Systemic Therapy for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease

Table 5: Recommendation 3 for HR+/HER2- Breast Cancer Breast Cancer

Table 6: The Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer, Edition 2018

Table 7: Total Incident Cases of Breast Cancer in the 7MM (2021-2034)

Table 8: Total Incident Cases of HR+/HER2– Breast Cancer in the 7MM (2021-2034)

Table 9: Total Incident Cases of Breast Cancer in the United States (2021-2034)

Table 10: Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Table 11: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in the United States (2021-2034)

Table 12: Stage-specific Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Table 13: Age-specific Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Table 14: Treatment-eligible Cases of HR+/HER2– Breast Cancer in the United States (2021-2034)

Table 15: Total Incidence of Breast Cancer in EU4 and the UK (2021-2034)

Table 16: Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Table 17: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in EU4 and the UK (2021-2034)

Table 18: Stage-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Table 19: Age-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Table 20: Treatment-eligible cases of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Table 21: Total Incidence of Breast Cancer in Japan (2021-2034)

Table 22: Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Table 23: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in Japan (2021-2034)

Table 24: Stage-specific Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Table 25: Age-specific Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Table 26: Treatment-eligible Cases of HR+/HER2– Breast Cancer in Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Molecular Subtypes of Breast Cancer

Figure 2: Working of Estrogen Receptor

Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains

Figure 4: ER Pathway and Mechanisms of Resistance

Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer

Figure 6: Molecular Pathways Involved in the Induction of Hormone Therapy Resistance in Estrogen Receptor-Positive Breast Cancer Cells

Figure 7: Total Incident Cases of Breast Cancer in the 7MM (2021-2034)

Figure 8: Total Incident Cases of HR+/HER2– Breast Cancer in the 7MM (2021-2034)

Figure 9: Total Incident Cases of Breast Cancer in the United States (2021-2034)

Figure 10: Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Figure 11: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in the United States (2021-2034)

Figure 12: Stage-specific Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Figure 13: Age-specific Incidence of HR+/HER2– Breast Cancer in the United States (2021-2034)

Figure 14: Treatment-eligible Pool for HR+/HER2– Breast Cancer in the United States (2021-2034)

Figure 15: Total Incidence of Breast Cancer in EU4 and the UK (2021-2034)

Figure 16: Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Figure 17: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in EU4 and the UK (2021-2034)

Figure 18: Stage-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Figure 19: Age-specific Incidence of HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Figure 20: Treatment-eligible Pool for HR+/HER2– Breast Cancer in EU4 and the UK (2021-2034)

Figure 21: Total Incidence of Breast Cancer in Japan (2021-2034)

Figure 22: Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Figure 23: Incidence of HR+/HER2– Breast Cancer Cases by Menopausal Status in Japan (2021-2034)

Figure 24: Stage-specific Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Figure 25: Age-specific Incidence of HR+/HER2– Breast Cancer in Japan (2021-2034)

Figure 26: Treatment-eligible Pool for HR+/HER2– Breast Cancer in Japan (2021-2034)

Tags:

License Type

Offer